TipRanks
Advertisement
Advertisement
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting
PremiumCompany AnnouncementsMinerva Neurosciences Updates Governance Following 2026 Shareholder Meeting
4M ago
Minerva Neurosciences Launches ATM Offering to Fund Trial
Premium
Company Announcements
Minerva Neurosciences Launches ATM Offering to Fund Trial
5M ago
Tsao Maintains Hold on Minerva as Roluperidone Phase 3 Progress Balances Rising Losses; $7 Price Target Reaffirmed
Premium
Ratings
Tsao Maintains Hold on Minerva as Roluperidone Phase 3 Progress Balances Rising Losses; $7 Price Target Reaffirmed
5M ago
Minerva appoints Jim O’Connor as chief business officer
PremiumThe FlyMinerva appoints Jim O’Connor as chief business officer
6M ago
Minerva screens first patient in roluperidone trial
Premium
The Fly
Minerva screens first patient in roluperidone trial
7M ago
Minerva price target raised to $7 from $4 at H.C. Wainwright
Premium
The Fly
Minerva price target raised to $7 from $4 at H.C. Wainwright
7M ago
Closing Bell Movers: UiPath up nearly 4% after S&P 400 admission
PremiumThe FlyClosing Bell Movers: UiPath up nearly 4% after S&P 400 admission
10M ago
Minerva files to sell 94.6M shares of common stock for holders
Premium
The Fly
Minerva files to sell 94.6M shares of common stock for holders
10M ago
Minerva Neurosciences Shareholders Approve Key Governance Measures
Premium
Company Announcements
Minerva Neurosciences Shareholders Approve Key Governance Measures
10M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―